CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...